Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 6/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8756417 | 0.88 | L3MBTL1 (0.71) | KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11752289 | 0.87 | KMT2A (0.74) | KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12410190 | 0.86 | KMT2A (0.64) | KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13918749 | 0.84 | KDM4E (0.70) | KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6360344 | 0.83 | NPC1 (0.75) | KMT2ANPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7621996 | 0.83 | RAB9A (0.62) | KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14601213 | 0.83 | NPC1 (0.51) | KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13295865 | 0.81 | NPC1 (0.60) | KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10294667 | 0.81 | NPC1 (0.81) | KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13753746 | 0.80 | KDM4E (0.62) | KMT2AL3MBTL1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | SCHARPE SIMON LODEWIJK (BE) | 2002-05-23 | — | — | US | disclosed |
| EP-1062222-A1 | SERINE PEPTIDASE MODULATORS | Fondatech Benelux N.V. (BE) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | FAP, CTSC, DPP4 | KMT2A 3602/4885L3MBTL1 2607/4885NPC1 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.